TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06469580

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NPLUS (neonatologist performed lung ultrasound)
Description: NPLUS is conducted with an ultrasound scanner using a high-frequency (12-15 MHz) linear transducer probe (scanning depth approximately 4-5 cm). The neonate is placed in a supine position. The anterior, lateral and posterior chest areas are scanned using the presets lung or small parts. Landmarks are the anterior and posterior axillary line (longitudinal) on each hemithorax. A sequential scan from right to left, anterior to posterior is performed. (6 lung areas). In the study NPLUS is performed to quantify the lung ultrasound score at time points T0, T1 and T2. Sequences of 3-5 seconds are saved and assessed according to the lung ultrasound score adapted by Rodriguez-Fanjul et al. (0- to 3 point score for each area, resulting in a total score ranging from 0 to 18). To ensure inter-observer reliability the anonymous video sequences are then rated by two independent neonatologists.
Study: NCT04879485

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Blood products
Description: Compare two different transfusion strategies against standard transfusion regimen

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Blood products
Description: Compare two different transfusion strategies against standard transfusion regimen
Study: NCT05297019

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyperbaric Oxygen Therapy
Description: hyperbaric oxygen therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyperbaric Oxygen Therapy
Description: hyperbaric oxygen therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyperbaric Oxygen Therapy
Description: hyperbaric oxygen therapy
Study: NCT06394219

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: traditional transperitoneal laparoscopic pyelolithotomy
Description: Performing anterior Pyelotomy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: modified transperitoneal laparoscopic pyelolithotomy
Description: Performing posterior pyelotomy
Study: NCT04843111

Intervention type: BIOLOGICAL
Intervention: Meningococcal polysaccharide (serogroups A, C, Y, and W) tetanus toxoid conjugate vaccine
Description: Pharmaceutical form: Solution for injection Route of administration: Intramuscular
Study: NCT06436313

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Sessions
Description: Two online educational sessions will be organized before DBS surgery. These will be scheduled between consultation with the neurologist and the consultation with the neurosurgeon. Each virtual session will last about 1 hour. Patients can login from home, together with their caregivers. The virtual sessions will be held on MS Teams virtual platform.~One of the sessions will include a DBS patient where patients will have the opportunity to ask peer-to-peer questions. The session includes testimonials from patient before and after their surgery.~The second session (about two weeks later) is a summary presentation, a quiz and time for Q\&A. During one of the sessions (first or second), a DBS patient (who has been implanted) can be invited to participate togive the attendees the opportunity to ask peer-to-peer questions. The quiz contains questions to assess the patients' knowledge of DBS.
Study: NCT05450055

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: intraperitoneal lidocaine analgesic or normal saline as control
Description: Before the end of surgery, patients in the experimental group (L group) were extensively sprayed with 20mL (100mg) 0.5% lidocaine intraperitoneally before the peritoneum was sutured. The surgeon placed intraperitoneal catheter with the catheter tip above the vaginal end while placing percutaneous drainage tube. The intraperitoneal catheter was connected to the electronic analgesia pump, and the infusion of 0.5% lidocaine 10mL/h was interrupted from 1 to 72h after surgery, with a total volume of 720mL in the pump.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intraperitoneal lidocaine analgesic or normal saline as control
Description: Before the end of surgery, patients in the experimental group (L group) were extensively sprayed with 20mL (100mg) 0.5% lidocaine intraperitoneally before the peritoneum was sutured. The surgeon placed intraperitoneal catheter with the catheter tip above the vaginal end while placing percutaneous drainage tube. The intraperitoneal catheter was connected to the electronic analgesia pump, and the infusion of 0.5% lidocaine 10mL/h was interrupted from 1 to 72h after surgery, with a total volume of 720mL in the pump.
Study: NCT05221125

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychologically-Informed Physical Therapy (PIPT)
Description: The PIPT group will receive evaluation and treatment based on the PT's assessment of the individual patient's clinical presentation and condition.
Study: NCT04914416

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Verum T7
Description: Verum T4 is a 34200AAIU/g white kidney bean extract. Daily dosage is 512 mg in 3 capsules

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Verum T7
Description: Verum T4 is a 34200AAIU/g white kidney bean extract. Daily dosage is 512 mg in 3 capsules

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Verum T7
Description: Verum T4 is a 34200AAIU/g white kidney bean extract. Daily dosage is 512 mg in 3 capsules
Study: NCT05414123

Intervention type: DEVICE
Intervention: CNSide
Description: The Cerebro-Spinal Fluid (CSF) of subjects enrolled into each cohort will be used for Standard of Care diagnostic assessments used for subjects with either confirmed or suspicious LM (Cytology, protein and glucose) in combination with CNSide analysis.

Intervention type: DEVICE
Intervention: CNSide
Description: The Cerebro-Spinal Fluid (CSF) of subjects enrolled into each cohort will be used for Standard of Care diagnostic assessments used for subjects with either confirmed or suspicious LM (Cytology, protein and glucose) in combination with CNSide analysis.
Study: NCT04914416

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Verum T7
Description: Verum T4 is a 34200AAIU/g white kidney bean extract. Daily dosage is 512 mg in 3 capsules
Study: NCT05315310

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Soft Exosuit
Description: A soft exosuit is a textile-based wearable robot that is worn on the paretic ankle. Soft exosuits provide assistive torques through retraction of Bowden cables that connect distally to anchor points on front and back of the ankle, assisting with dorsiflexion during swing for foot clearance, and plantarflexion during late stance to assist with propulsion, respectively. Exosuit assistance is provided synchronously based on the wearer's gait, as detected by integrated inertial measurement units.
Study: NCT03873207

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PopSole™ offloading device
Description: Offload Device Distribution to remain in use at all times during ambulation and activity instruction to stay off of feet as much as possible for 3 days, then limit ambulation to 10 minutes per hour for 4 weeks and no sports, kicking, running or exercise for 4 weeks. Devices will be provided for both feet to maintain symmetry and gait stability between the two feet.

Intervention type: DEVICE
Group type: OTHER
Intervention: padded insole
Description: the control arm will be provided with standard padded insole to wear inside footwear
Study: NCT04914416

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Verum T7
Description: Verum T4 is a 34200AAIU/g white kidney bean extract. Daily dosage is 512 mg in 3 capsules

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Verum T7
Description: Verum T4 is a 34200AAIU/g white kidney bean extract. Daily dosage is 512 mg in 3 capsules

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Verum T7
Description: Verum T4 is a 34200AAIU/g white kidney bean extract. Daily dosage is 512 mg in 3 capsules

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Verum T7
Description: Verum T4 is a 34200AAIU/g white kidney bean extract. Daily dosage is 512 mg in 3 capsules

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Verum T7
Description: Verum T4 is a 34200AAIU/g white kidney bean extract. Daily dosage is 512 mg in 3 capsules
Study: NCT06014424

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBD
Description: Participants in this arm will receive CBD for 8 weeks during the first treatment period. They will then receive a two-week single-blind placebo washout before moving into the second 8-week treatment period, during which they will receive the opposite study treatment than the one given in the first treatment period.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants in this arm will receive placebo for 8 weeks during the first treatment period. They will then receive a two-week single-blind placebo washout before moving into the second 8-week treatment period, during which they will receive the opposite study treatment than the one given in the first treatment period.
Study: NCT06562465

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dietary and exercise management
Description: Dietary and exercise management: dietary management by providing tailored recipes, health education lectures, science competitions, etc；exercise management:develop weekly and monthly exercise plans for children of different ages, and have physical education teachers lead them in exercising.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: no dietary and exercise management
Description: NO dietary and exercise management:do not implement dietary and exercise management related to the experimental group
Study: NCT05333107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0385-0434 G
Description: Participants will receive oral dose of NNC0385-0434 G tablet either for the initial 10-day treatment period (period 1) or 5-day treatment period (period 2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0385-0434 G
Description: Participants will receive oral dose of NNC0385-0434 G tablet either for the initial 10-day treatment period (period 1) or 5-day treatment period (period 2).
Study: NCT04914416

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Verum T7
Description: Verum T4 is a 34200AAIU/g white kidney bean extract. Daily dosage is 512 mg in 3 capsules

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Verum T8
Description: Verum T8 is a 34200AAIU/g white kidney bean extract. Daily dosage is 190 mg in 3 capsules.
Study: NCT05333107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0385-0434 G
Description: Participants will receive oral dose of NNC0385-0434 G tablet either for the initial 10-day treatment period (period 1) or 5-day treatment period (period 2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0385-0434 G
Description: Participants will receive oral dose of NNC0385-0434 G tablet either for the initial 10-day treatment period (period 1) or 5-day treatment period (period 2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0385-0434 F
Description: Participants will receive oral dose of NNC0385-0434 F tablet either for the initial 10-day treatment period (period 1) or 5-day treatment period (period 2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0385-0434 F
Description: Participants will receive oral dose of NNC0385-0434 F tablet either for the initial 10-day treatment period (period 1) or 5-day treatment period (period 2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0385-0434 F
Description: Participants will receive oral dose of NNC0385-0434 F tablet either for the initial 10-day treatment period (period 1) or 5-day treatment period (period 2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0385-0434 F
Description: Participants will receive oral dose of NNC0385-0434 F tablet either for the initial 10-day treatment period (period 1) or 5-day treatment period (period 2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0385-0434 B
Description: Participants will receive oral dose of NNC0385-0434 B tablet either for the initial 10-day treatment period (period 1) or 5-day treatment period (period 2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0385-0434 B
Description: Participants will receive oral dose of NNC0385-0434 B tablet either for the initial 10-day treatment period (period 1) or 5-day treatment period (period 2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0385-0434 B
Description: Participants will receive oral dose of NNC0385-0434 B tablet either for the initial 10-day treatment period (period 1) or 5-day treatment period (period 2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0385-0434 B
Description: Participants will receive oral dose of NNC0385-0434 B tablet either for the initial 10-day treatment period (period 1) or 5-day treatment period (period 2).
Study: NCT04914416

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Verum T8
Description: Verum T8 is a 34200AAIU/g white kidney bean extract. Daily dosage is 190 mg in 3 capsules.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Verum T8
Description: Verum T8 is a 34200AAIU/g white kidney bean extract. Daily dosage is 190 mg in 3 capsules.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Verum T8
Description: Verum T8 is a 34200AAIU/g white kidney bean extract. Daily dosage is 190 mg in 3 capsules.
Study: NCT04985435

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Filgotinib
Description: 200 mg tablet once daily or 100 mg once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Filgotinib
Description: 200 mg tablet once daily or 100 mg once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti-Tumor Necrosis Factor Alpha Drug (Product)
Description: Adalimumab subcutaneous injections 40 mg once every two weeks Etanercept subcutaneous injections 50 mg weekly
Study: NCT05975125

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin C 500 MG Oral Tablet
Description: compare between Vitamin C with iron supplement and iron supplement alone in prevention of anemia in pregnancy.
Study: NCT06652828

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Treadmill Walking (CTT)
Description: The CTT serves as a comparison to PBT. It involves standard treadmill walking without perturbations on the same treadmill. This intervention is conducted over the same defined period as PBT (3-6 weeks), with a matched frequency and exercise time compared to the PBT group for consistency. Participants are secured with safety harnesses while walking.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Perturbation-Based Balance Training (PBT)
Description: Overall, 9 training sessions with different objectives and progression regarding perturbation directions, predictability, and intensity will be conducted within 3-6 weeks. During the initial sessions, familiarizing participants with the treadmill and establishing their individual walking pace will be focused. Pace can be individually adjusted in each training session. Participants are secured with safety harnesses while walking.
Study: NCT04914416

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Verum T8
Description: Verum T8 is a 34200AAIU/g white kidney bean extract. Daily dosage is 190 mg in 3 capsules.
Study: NCT04985435

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti-Tumor Necrosis Factor Alpha Drug (Product)
Description: Adalimumab subcutaneous injections 40 mg once every two weeks Etanercept subcutaneous injections 50 mg weekly
Study: NCT04928404

Intervention type: PROCEDURE
Group type: OTHER
Intervention: tongue base suspension using barbed suture
Description: all patients will undergo multi-level surgeries .Therefor, Anterolateral advancement pharyngeoplasty (ALA) or Barbed Reposition Pharyngoplasty (BRP) will be applied to improve retro-palatal obstruction and tongue base suspension using barbed suture for retro-lingual obstruction.
Study: NCT04985435

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 50 patients will have a Free Choice between Filgotinib and anti TNF
Description: 50 patients will be given the opportunity to choose between either TNFi (etanercept 50 mg SC once a week or adalimumab 40 mg SC once every two weeks) or filgotinib, an oral JAKi, 200 mg once a day while another group of 50 patients will be randomized to the same treatment arms.
Study: NCT05377164

Intervention type: BEHAVIORAL
Intervention: food choices
Description: Analysis of lymphocytes isolated from the peripheral blood of participants who had been on vegetarian, ketogenic or normal mixed diet for at least one year will be performed.

Intervention type: BEHAVIORAL
Intervention: food choices
Description: Analysis of lymphocytes isolated from the peripheral blood of participants who had been on vegetarian, ketogenic or normal mixed diet for at least one year will be performed.

Intervention type: BEHAVIORAL
Intervention: food choices
Description: Analysis of lymphocytes isolated from the peripheral blood of participants who had been on vegetarian, ketogenic or normal mixed diet for at least one year will be performed.
Study: NCT04779827

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Social Network and Collective Intelligence Intervention
Description: The online network intervention aims to use different configurations of online social networks to optimize the impacts of collective intelligence process to improve individuals' understanding, beliefs, and behavioral choices regarding a variety of health behaviors. Participants will be put into different online networks and respond to health questions while receiving feedback from their network members.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Social Network and Collective Intelligence Intervention
Description: The online network intervention aims to use different configurations of online social networks to optimize the impacts of collective intelligence process to improve individuals' understanding, beliefs, and behavioral choices regarding a variety of health behaviors. Participants will be put into different online networks and respond to health questions while receiving feedback from their network members.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Social Network and Collective Intelligence Intervention
Description: The online network intervention aims to use different configurations of online social networks to optimize the impacts of collective intelligence process to improve individuals' understanding, beliefs, and behavioral choices regarding a variety of health behaviors. Participants will be put into different online networks and respond to health questions while receiving feedback from their network members.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Social Network and Collective Intelligence Intervention
Description: The online network intervention aims to use different configurations of online social networks to optimize the impacts of collective intelligence process to improve individuals' understanding, beliefs, and behavioral choices regarding a variety of health behaviors. Participants will be put into different online networks and respond to health questions while receiving feedback from their network members.
Study: NCT06057337

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Families with Pride (Familias con Orgullo)
Description: Families with Pride (Familias con Orgullo) aims to prevent the co-occurring epidemics of drug use and depression in Hispanic sexual minority youth. It focuses on improving parent support for the adolescent, parent acceptance of the adolescent, family functioning (e.g., communication), and decreasing stress and sexual minority stress. The program consists of 11 weekly, in-person sessions: 7 parent group sessions, 3 concurrent adolescent group sessions, both lasting two hours, 4 family sessions lasting 1 hour in either Spanish or English, depending on participant language preference. In the parent group sessions, parents come together to foster social support, family functioning, and increase parental support and acceptance for the adolescent. In the adolescent sessions, adolescents build skills in confronting and managing stressors related to being a sexual minority.
Study: NCT05263245

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Light breakfast
Description: Light breakfast, standardized by 7 menu options for patients. All breakfast options contain the same amount of fat (9-10 g). Example of a menu: 150 ml full-fat yoghurt, 40 gram muesli with sugar, 1 glass of tea.
Study: NCT06673199

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Washoku diet
Description: The Washoku diet will consist of following the principles of a healthy eating plate, which will be supplemented with elements of the Washoku diet (30g of roasted black soybeans and 5g of wakame). Food products will be given to women on the day of the first meeting. The Washoku diet will be used for 7 days a week for a period of 1 month (4 weeks).
Study: NCT06602752

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Food system and demand generation
Description: The Vegetables for All project will create FFZs in low-income urban and peri-urban areas. FFZs are the last mile/point of purchase for delivering a variety of fresh, safe, and accessible vegetables to BoP households. The program will link vendors and farmers through market facilitators, support the uptake of digital solutions for vendors to access vegetables, and support district governments to improve market infrastructure. To encourage BoP parents of children 3-9 years to buy and consume more vegetables, the program will include a demand generation component.
Study: NCT06543589

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-flow-nasal-cannula
Description: Respiratory support will be provided by devices that deliver a blend of heated and humidified gas mixture of air and oxygen at gas flows exceeding 8 L/ min via binasal cannula.
Study: NCT06594159

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY4065967
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY4065967
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY4065967
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY4065967
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Administered orally